High-dose chemotherapy for germ cell tumors: do we have a model?

Bibliography

• Feldman DR, Bosl GJ, Sheinfeld J, et al. Medical treatment of advanced testicular cancer. JAMA 2008;299:672-84
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Nicolai N, Tana S, et al. IGG practice guidelines on germ cell tumor in adult male patients. Tumori 2008;94:96-109
   PubMed Web of Science ®Google Scholar
• International Germ Cell Collaborative Group: international Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603
   PubMed Web of Science ®Google Scholar
• Albany C, Satpute SR, Brames MJ, et al. A retrospective analysis of patients with intermediate-risk germ cell tumor (IRGCT) treated at Indiana University from 2000 to 2010. J Clin Oncol 2012;30(Suppl):abstract 4534
   Google Scholar
• Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40
   PubMed Web of Science ®Google Scholar
• Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 1998;16:1287-93
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005;23:6549-55
   PubMed Web of Science ®Google Scholar
• Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010;28:1706-13
   PubMed Web of Science ®Google Scholar
• Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ cell cancer. Ann Oncol 2013;24:878-88
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003;21:4083-91
   PubMed Web of Science ®Google Scholar
• Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol 2012;30:800-5
   PubMed Web of Science ®Google Scholar
• Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized trial of the German Testicular Cancer Study Group. J Clin Oncol 2007;25:2778-84
   PubMed Web of Science ®Google Scholar
• Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011;29:2178-84
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000;18:1173-80
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;26:340-8
   Web of Science ®Google Scholar
• Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638-45
   PubMed Web of Science ®Google Scholar
• Fossa SD, Stenning SP, Gerl A, et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 1999;80:1392-9
   PubMed Web of Science ®Google Scholar
• Gerl A, Clemm C, Schmeller N, et al. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 1995;72:1026-32
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-18
   PubMed Web of Science ®Google Scholar
• International Prognostic Factors Study Group. Lorch A, Beyer J, Bascoul-Mollevi C, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010;28:4906-11
   PubMed Web of Science ®Google Scholar
• Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 1993;23:213-17
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993;85:1828-35
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997;15:2546-52
   PubMed Web of Science ®Google Scholar
• Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 1994;12:1223-31
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Schmoll HJ, Harstrick A, et al. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide, and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Eur J Cancer 1993;29A:2225-31
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nichols CR, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007;25:247-56
   PubMed Web of Science ®Google Scholar
• Droz JP, Kramar A, Biron P, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007;51:739-48
   PubMed Web of Science ®Google Scholar
• Daugaard G, Skoneczna IA, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011;22:1054-61
   PubMed Web of Science ®Google Scholar
• Necchi A, Mariani L, Di Nicola M, et al. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment for patients with poor prognosis germ cell tumors: mature results of an Italian randomized phase II study. Ann Oncol 2014; Accepted, in press
   Google Scholar
• van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 2006;42:820-6
   PubMed Web of Science ®Google Scholar
• Farè E, Lo Vullo S, Giannatempo P, et al. Clinical outcomes of poor prognosis germ cell tumors (GCT): an analysis of a series from a single referral center [abstract 859P]. European Society for Medical Oncology (ESMO) annual meeting; 26 – 30th September 2014; Madrid, Spain
   Google Scholar
• Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2004;15:79-87
   PubMed Web of Science ®Google Scholar
• Schwella N, Beyer J, Schwaner I, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996;14:1114-21
   PubMed Web of Science ®Google Scholar
• Necchi A, Miceli R, Pedrazzoli P, et al. Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy. Clin Genitourin Cancer 2014;12:196-202
   PubMed Web of Science ®Google Scholar
• Kobold S, Isernhagen J, Hubel K, et al. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant 2011;46:1053-6
   PubMed Web of Science ®Google Scholar
• Necchi A, Badoglio M, Miceli R, et al. Analysis of the contemporary use of high-dose chemotherapy (HDCT) in germ cell tumors (GCT) in Europe: early findings of an ongoing EBMT-sponsored study. J Clin Oncol 2014;32(Suppl):abstract e15536
   Google Scholar
• Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 1994;12:1223-31
   PubMed Web of Science ®Google Scholar
• Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000;18:3346-51
   PubMed Web of Science ®Google Scholar
• Necchi A, Miceli R, Berger LA, et al. Impact of response to induction chemotherapy in patients with germ cell tumors (GCT) receiving salvage high-dose chemotherapy (HDCT): a study of the EBMT solid tumors working party (STWP) [abstract 860P]. European Society for Medical Oncology (ESMO) annual meeting; 26 – 30th September 2014; Madrid, Spain
   Google Scholar
• Toner GC, Geller NL, Tan C, et al. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990;50:5904-10
   PubMed Web of Science ®Google Scholar
• Murphy BA, Motzer RJ, Mazumdar M, et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 1994;73:2520-6
   PubMed Web of Science ®Google Scholar
• Gerl A, Clemm C, Lamerz R, et al. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer 1993;29A:961-5
   Google Scholar
• Gerl A, Lamerz R, Clemm C, et al. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 1996;2:1565-70
   PubMed Web of Science ®Google Scholar
• Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004;22:3868-76
   PubMed Web of Science ®Google Scholar
• Fizazi K, Pagliaro LC, Flechon A, et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13. J Clin Oncol 2013;31(Suppl):abstract LBA4500
   Google Scholar
• Massard C, Kramar A, Beyer J, et al. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol 2013;24:322-8
   PubMed Web of Science ®Google Scholar
• Meisel JL, Woo K, Sudarsan N, et al. Female germ cell tumors(GCT): the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol 2014;32(5 Suppl):abstract 5539
   Google Scholar
• Lorch A, Rick O, Wundisch T, et al. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J Urol 2010;184:168-73
   PubMed Web of Science ®Google Scholar
• Albany C, Einhorn LH. Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol 2013;25:261-5
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Nichols CR, Meisner C, et al. Identification of prognostic subgroups among patients with metastatic “IGCCCG poor-prognosis” germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol 2000;11:1115-20
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002;20:1864-73
   PubMed Web of Science ®Google Scholar
• Banna GL, De Giorgi U, Ferrari B, et al. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? Biol Blood Marrow Transplant 2006;12:1085-91
   PubMed Web of Science ®Google Scholar
• Rosti G, De Giorgi U, Wandt H, et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 2004;34:1033-7
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Schleucher N, Metzner B, et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 2003;89:29-35
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Demirer T, Wandt H, et al. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol 2005;16:146-51
   PubMed Web of Science ®Google Scholar
• Necchi A, Giannatempo P, Lo Vullo S, et al. A prognostic model including pre- and post-surgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors (PMNSGCT): the 27-year experience of a referral center. Clin Genitourin Cancer 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Pagliaro LC, Laplanche A, Flechon A, et al. Validation of a prognostic classification system for mediastinal nonseminomatous germ-cell tumors (MGCT). J Clin Oncol 2014;32(5 Suppl):abstract 4562
   Google Scholar
• Agarwala AK, Perkins SM, Abonour R, et al. Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. Am J Clin Oncol 2011;34:286-8
   PubMed Web of Science ®Google Scholar
• Papiani G, Einhorn LH. Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases. Bone Marrow Transplant 2007;40:235-7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996;14:1098-105
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, de Wit R, de Mulder PH, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999;10:1467-73
   PubMed Web of Science ®Google Scholar
• Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001;19:81-8
   PubMed Web of Science ®Google Scholar
• Vaena DA, Abonour R, Einhorn LH, et al. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003;21:4100-4
   PubMed Web of Science ®Google Scholar
• Lotz JP, Bui B, Gomez F, et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol 2005;16:411-18
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin oncol 2007;25:85-90
   PubMed Web of Science ®Google Scholar
• Lorch A, Neubauer A, Hackenthal M, et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol 2010;21:820-5
   PubMed Web of Science ®Google Scholar
• Selle F, Wittnebel S, Biron P, et al. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the multicentric TAXIF II study. Ann Oncol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Hartmann JT, Gauler T, Metzner B, et al. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 2007;25:5742-7
   PubMed Web of Science ®Google Scholar